Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 3
1947 2
1949 2
1972 2
1973 5
1974 1
1975 6
1976 2
1977 3
1978 2
1982 2
1984 2
1985 2
1986 1
1988 2
1989 1
1990 1
1991 7
1992 4
1993 6
1994 5
1995 6
1996 5
1997 2
1998 3
1999 3
2000 4
2001 3
2002 3
2003 4
2004 9
2005 8
2006 9
2007 6
2008 5
2009 7
2010 8
2011 5
2012 5
2013 5
2014 9
2015 11
2016 9
2017 11
2018 14
2019 9
2020 10
2021 9
2022 7
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüßmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P. Wilson MR, et al. Among authors: rusconi c. Blood. 2022 Apr 21;139(16):2499-2511. doi: 10.1182/blood.2021014506. Blood. 2022. PMID: 34995350 Free article.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Among authors: rusconi c. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.
Platelet functions beyond hemostasis.
Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman HL, Becker RC; 2009 Platelet Colloquium Participants. Smyth SS, et al. J Thromb Haemost. 2009 Nov;7(11):1759-66. doi: 10.1111/j.1538-7836.2009.03586.x. Epub 2009 Aug 19. J Thromb Haemost. 2009. PMID: 19691483 Free article. Review.
The potential of aptamers as anticoagulants.
Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. Nimjee SM, et al. Among authors: rusconi cp. Trends Cardiovasc Med. 2005 Jan;15(1):41-5. doi: 10.1016/j.tcm.2005.01.002. Trends Cardiovasc Med. 2005. PMID: 15795162 Review.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Giné E, Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer RL, Pagani C, Duglosz-Danecka M, Mocikova H, van Meerten T, Cencini E, Marin-Niebla A, Williams ME, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C. Rusconi C, et al. Blood. 2022 Oct 27;140(17):1907-1916. doi: 10.1182/blood.2022015560. Blood. 2022. PMID: 35789260 Free article.
Factor IXa inhibitors as novel anticoagulants.
Howard EL, Becker KC, Rusconi CP, Becker RC. Howard EL, et al. Among authors: rusconi cp. Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):722-7. doi: 10.1161/01.ATV.0000259363.91070.f1. Epub 2007 Feb 1. Arterioscler Thromb Vasc Biol. 2007. PMID: 17272750 Review.
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M, Frigeni M, Alric L, Visco C, Besson C, Mannelli L, Di Rocco A, Ferrari A, Farina L, Pirisi M, Piazza F, Loustaud-Ratti V, Arcari A, Marino D, Sica A, Goldaniga M, Rusconi C, Gentile M, Cencini E, Benanti F, Rumi MG, Ferretti VV, Grossi P, Gotti M, Sciarra R, Tisi MC, Cano I, Zuccaro V, Passamonti F, Arcaini L. Merli M, et al. Among authors: rusconi c. Oncologist. 2019 Aug;24(8):e720-e729. doi: 10.1634/theoncologist.2018-0331. Epub 2018 Dec 14. Oncologist. 2019. PMID: 30552159 Free PMC article.
Aptamers: an emerging class of therapeutics.
Nimjee SM, Rusconi CP, Sullenger BA. Nimjee SM, et al. Among authors: rusconi cp. Annu Rev Med. 2005;56:555-83. doi: 10.1146/annurev.med.56.062904.144915. Annu Rev Med. 2005. PMID: 15660527 Review.
243 results